Get The Best Bio Adhesive Wound Dressing Solution To Stop Severe Bleeding Immediately

Axio announced that their cutting-edge hemostatic product Axiostat has been officially approved by the USFDA thus could soon be available for private, commercial and institutional clients in the US.

ID: 1538237
recent pressrelease next pressrelease

(businesspress24) - Axio, a company specializing in cutting-edge wound care products, launched Axiostat, an FDA-approved chitosan-based wound dressing designed to stop profuse bleeding. Using a novel biomaterial platform, Axiostat forms a mechanical seal through its bio-adhesive properties, thus stopping bleeding much more quickly than conventional cotton gauze.

More information can be found at

The most widely used means of stopping bleeding is standard cotton gauze, a potentially inefficient solution against profuse bleeding. Studies show that more than 1.25 million people die each year due to severe bleeding following auto accidents, making it essential for health care providers to invest in a more efficient hemostatic solution.

Axiostat, the innovative wound dressing product developed by Axio Biosolutions, has now officially been approved by the USFDA and the CE, making it the most efficient hemostatic solution currently available to the public.

The wound dressing is based on chitosan, a substance obtained from treating the shell of shrimp and other crustaceans. Axiostat is highly bio-adhesive, quickly forming a barrier which prevents blood loss by concentrating plasma, protein and cellular components at the wound site.

Axiostat has various applications for successful use in different fields, including vascular, dental, emergency trauma and military healthcare. The product is currently the standard homeostatic solution of defense forces throughout the world, including the Indian Armed Forces, having helped save numerous lives in military and civilian emergencies. Axio is also developing various kits for industries and automobiles along with Rapid Prototype partners - MakeIn3D.

Leo Mavely, the CEO and founder of Axio Biosolutions, said: The FDA clearance of Axiostat in the US is a major milestone in our journey so far. This is a validation of the performance, safety and efficacy of Axiostat in bleeding control. We developed Axiostat to be a world-class quality product and this clearance reiterates that. We could not have done it without the trust and support of our entire team as well as investors.

Interested parties can find more information by visiting the above-mentioned website.

More information:

Keywords (optional):

axio, approved, institutional, commercial, private, available, soon, could, thus, usfda,

Company information / Profile:


PressRelease by


#541, 5th main, 16th cross, Indiranagar 2nd stage,

PressContact / Agency:

published by: alekspressdev
print pressrelease  send to a friend  

Date: 07/09/2018 - 03:59
Language: English
News-ID 1538237
Character count: 2517
Firma: Axiobio
Ansprechpartner: Axiobio Feedback to about Pressrelease-id:
Stadt: Bangalore
Telefon: +91-88607-86067

Meldungsart: Unternehmensinformation
Versandart: Veröffentlichung
Freigabedatum: 09/07/2018

Number of hits: 355


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 149
Register today: 0
Register yesterday: 4
Members online: 0
Guests online: 51

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.